结肠直肠癌治疗的当前和未来趋势:探索免疫疗法的进展
Taxiarchis Konstantinos Nikolouzakis1, Emmanuel Chrysos1, Anca Oana Docea2
1Department of General Surgery, University General Hospital of Heraklion, 71110 Heraklion, Greece.
新的癌症疗法,包括免疫检查点抑制剂 (ICI) 和端粒向治疗,通过解决治疗停滞,有望改善结直肠癌 (CRC) 的结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 分子生物学分子生物学
背景情况:
- 结肠直肠癌 (CRC) 仍然是全球癌症相关死亡的主要原因.
- 尽管在手术和化疗方面取得了进展,但CRC的生存率改善已经停滞不前.
- 新的治疗策略对于提高CRC患者的治疗结果至关重要.
研究的目的:
- 审查结直肠癌免疫疗法的进展,包括免疫检查点抑制剂 (ICI) 和采用细胞疗法 (ACT).
- 探索端粒长度改变在CRC致癌的作用及其治疗潜力.
- 检查免疫疗法和针对CRC的端粒向疗法之间的潜在协同作用.
主要方法:
- 关于CRC免疫疗法的临床前和临床研究的文献综述.
- 对结直肠癌发展中的端粒生物学研究的分析.
- 探索结合治疗策略,整合免疫疗法和端粒向.
主要成果:
- 像ICI和ACT这样的新兴免疫疗法在临床前和临床CRC环境中显示出显著的前途.
- 改变端粒长度是CRC启动的一个关键因素,导致染色体不稳定.
- 以端粒为向的疗法代表了治疗CRC的新方法.
结论:
- 结合免疫疗法和端粒向疗法可能为结直肠癌治疗提供协同效益.
- 对这些交叉模式的进一步研究可能会提高疗效和患者的治疗结果.
- 新型治疗组合有望克服CRC当前的治疗局限性.
更多相关视频
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
相关概念视频
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
